New drug aims to stop kidney disease from coming back after transplant
NCT ID NCT04572854
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so results are not conclusive, but it may point toward a new way to manage this difficult condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegcetacoplan
- What this could lead to
- If it works, this could offer a way to control recurring kidney disease after transplant, potentially preserving the transplant longer.
- What could go wrong
- This is a very small, early-phase study with only 13 participants. The results may not apply to all patients, and the drug may not prove effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUV
Lausanne, 1005, Switzerland
-
CUIMC
New York, New York, 10032, United States
-
Center Hospitalier Universitaire de Montpellier
Montpellier, 34295 CEDEX 5, France
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Clinical Research Center, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, 05403-000, Brazil
-
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Hopital Edouard Herriot, Hospices Civils de Lyon
Lyon, 69437, France
-
Hospital Universitario 12 de Octubre, Nephrology Department
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Favaloro
Buenos Aires, C1093AAS, Argentina
-
Hospital de Alta Complejidad en Red El Cruce Dr. Nestor Carlos Kirchner
San Juan Bautista, Buenos Aires, B1888AAE, Argentina
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
-
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Ranica, 24020, Italy
-
Keck School of Medicine, University of Southern California
Los Angeles, California, 900033, United States
-
Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology
Lille, 59000, France
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Medical University of Vienna
Vienna, 1090, Austria
-
Monash Medical Centre
Clayton, 3168, Australia
-
NYU Langone Health Transplant Insitute
New York, New York, 10016, United States
-
Radbound University Medical Center
Nijmegen, 6500 HB, Netherlands
-
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, CEP 30150-221, Brazil
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP
Botucatu, São Paulo, 18618-686, Brazil
-
Washington University, St.Louis
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the type of anesthesia affect kidney transplant success?
- New drug aims to fight skin cancer in transplant patients
- New ultrasound technique could predict kidney transplant success without needles
- Kidney transplant study compares immune effects of two common drugs
- Scientists probe immune cells to predict transplant rejection
- New drug iptacopan studied for rare kidney disease C3G